股东委托书协议
Intra-cellular(ITCI)04-30 04:15
$Intra-cellular(ITCI)$ DEF 14A Other definitive proxy statements Accession Number: 0001628280-24-018986 Act: 34 Size: 6 MB 网页链接
简介:Intra-cellular Therapies, Inc.(内细胞疗法公司)于2001年5月22日在美国特拉华州注册成立,并于2002年6月开始运营。公司的创立旨在开发药物用于神经和精神疾病的治疗。 ITI公司是一家生物制药公司,专注于创新和发展临床的小分子药物,来改善针对中枢神经系统内精神障碍缺医少药的医疗条件。公司主导产品, ITI- 007 ,临床发展为治疗精神分裂症一流药物。目前用于治疗精神分裂症的药物也没有完全解决中枢神经系统疾病的一系列症状。这些现有的药物也被他们强大的副作用限制。 ITI- 007是用来治疗很多症状,包括急性和残余精神分裂症,具有改进后的安全性和耐受性。
今开:81.16 | 昨收:80.84 |
最高:82 | 最低:79.43 |
涨停价: | 跌停价: |
总市值:8487162593 |
Intra-cellular(ITCI)04-30 04:15
$Intra-cellular(ITCI)$ DEF 14A Other definitive proxy statements Accession Number: 0001628280-24-018986 Act: 34 Size: 6 MB 网页链接
Intra-cellular(ITCI)05-07 19:45
$Intra-cellular(ITCI)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001193125-24-132586 Act: 34 Size: 245 KB 网页链接
Intra-cellular(ITCI)06-19 17:25
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-075082 Size: 7 KB 网页链接
Intra-cellular(ITCI)06-26 06:15
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077472 Size: 6 KB 网页链接
Intra-cellular(ITCI)07-03 08:05
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080987 Size: 4 KB 网页链接
SeekingBiotech06-18 21:55
ITCI Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder $Intra-cellular(ITCI)$ cns 重度抑郁,积极信号
Intra-cellular(ITCI)06-22 06:05
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-076380 Size: 10 KB 网页链接
Intra-cellular(ITCI)07-03 08:05
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080986 Size: 4 KB 网页链接
Intra-cellular(ITCI)06-26 06:15
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077469 Size: 8 KB 网页链接
Intra-cellular(ITCI)04-30 04:55
$Intra-cellular(ITCI)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-122651 Act: 34 Size: 1 MB 网页链接
SeekingBiotech06-18 21:55
ITCI Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder $Intra-cellular(ITCI)$ cns 重度抑郁,积极信号查看全文
chuminhua04-17 16:24
4/16,Intra-Cellular Therapies $Intra-cellular(ITCI)$ 周二表示,针对重度抑郁症 (MDD) 患者进行的 Caplyta (lumateperone) 的 III 期研究达到了主要终点和关键次要终点,使该药物距离获得更广泛的适应症批准又近了一步。 该消息推动公司股价上涨近28%。
首席医疗官 Suresh Durgam 表示:“...查看全文
确定性required03-30 21:56
$Intra-cellular(ITCI)$ I'd like to take a bet on it. MDD.查看全文
逍遥投资派2023-05-20 23:09
$Intra-cellular(ITCI)$ 2020年开始产生比较有意义的营收后连续大幅增长,2022年达到2.5亿,营业利润和净利润反而亏损加大,目前看不到投资价值。查看全文
chuminhua2023-03-29 17:00
3月28日,Intra-Cellular Therapies $Intra-cellular(ITCI)$ 报告称,Caplyta(lumateperone)有助于显著降低重度抑郁症(MDD)混合特征患者和双相抑郁症混合特征患者的抑郁症状严重程度。 消息传出后,公司股价上涨了 15%。
研究 403 旨在评估非典型抗精神病药物作为单一疗法治疗与 MDD 或双...查看全文
SeekingBiotech2023-03-28 23:59
$Intra-cellular(ITCI)$
ITCI Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with MDD with Mixed Features and Bipolar Depression with Mixed Features #CNS#查看全文
老王爱配置2022-09-13 19:31
$Intra-cellular(ITCI)$ $绿叶制药(02186)$ ITCI值五十亿美金啊查看全文
美股滚雪球2022-07-22 14:13
CNS药物领域不错的公司:$Xenon制药(XENE)$ &$Intra-cellular(ITCI)$ 被收购的概率比较大。
$恒瑞医药(SH600276)$查看全文
令狐不冲9992021-12-21 22:00
12.21关注:$qrnx $itci $Prelude(PRLD)$ $Intra-cellular(ITCI)$查看全文
产业链观察2021-12-20 19:56
药闻| 2021年12月20日,专注于中枢神经系统(CNS)疾病疗法开发和商业化的生物制药公司$Intra-cellular(ITCI)$ 今天宣布美国食品和药物管理局(FDA)批准CAPLYTA用于治疗与成人双相I型或II型疾病相关的抑郁症发作,可作为单药治疗,也可作为锂或丙戊酸钠的辅助治疗。查看全文
瑞银:下调Intra-Cellular Therapies(ITCI.US)评级,由买入调整至中性评级,目标价由85.00美元调整至83.00美元。 Intra-Cellular Therapies(ITCI.US)公司简介:Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公... 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080986 Size: 4 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080987 Size: 4 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077468 Size: 12 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077472 Size: 6 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077469 Size: 8 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-077470 Size: 6 KB 网页链接
$Intra-cellular(ITCI)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-167897 Act: 33 Size: 299 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-076380 Size: 10 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-075077 Size: 7 KB 网页链接
$Intra-cellular(ITCI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-075081 Size: 7 KB 网页链接